Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges

Shalini Arunogiri, Nicholas Lintzeris

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)


The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.

Original languageEnglish
Article number108221
Number of pages3
JournalJournal of Substance Abuse Treatment
Publication statusPublished - 1 May 2021


  • Buprenorphine
  • Opioid
  • Opioid use disorder

Cite this